Clinical trial
A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression (The CHAPERONE Study)
NCT03942419 is registered in ClinicalTrials.gov with Eyenovia Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression (The CHAPERONE Study)
- Lead sponsor
- Eyenovia Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- June 3, 2019
- Completion date
- November 20, 2024
- Enrollment
- 438 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.